Comments
Commented by Fabian Lorenz on July 29th, 2025 | 07:00 CEST
YIELD MONSTERS 2025: Hensoldt, Steyr Motors, Veganz shares – another 250% gain?
When it comes to German return monsters for 2025, investors rightly think primarily of defense companies like Rheinmetall, RENK, Hensoldt, and Steyr Motors. However, with a 250% gain, the Veganz Group may well be the surprise of the year. The Company is currently reinventing itself and attacking a billion-dollar market. Analyst estimates appear to be far too conservative and are likely to be revised upward soon. The stock, therefore, remains very attractive. Hensoldt has multiplied in value in recent years and is now supplying radar systems for the protection of Ukraine. The order volume is in the mid-three-digit million range. Steyr Motors will have to grow to this revenue range in the coming years to justify its current valuation. Analysts nevertheless recommend buying the stock.
Read
Commented by André Will-Laudien on July 28th, 2025 | 07:25 CEST
Gold and silver rally in 2025 – Panic buying ahead! Silver North, BYD, and VW in the fast lane!
Silver has long since ceased to be gold's little brother! Over the past 12 months, silver has clearly outperformed its big brother, rising 38% compared to a 27% increase in gold. This is due to several factors. Firstly, there are only around 240 active silver mines worldwide, compared to 1,350 gold mines. In recent years, silver has established itself as an industrial metal, as it is in high demand in high-tech, e-mobility, defense, and medical applications. This means that less and less of the coveted metal is left for the investment market, and physical stocks on the futures markets are also declining steadily. The time has therefore come to allocate some of your portfolio to silver, the little brother of gold, which has performed well. Silver explorers and developers offer the greatest leverage. Here are a few ideas.
Read
Commented by Nico Popp on July 28th, 2025 | 07:20 CEST
Hydrogen in Germany – Who will solve the "chicken and egg problem"? Pure Hydrogen, thyssenkrupp, NEL
Germany aims to achieve climate neutrality within twenty years. Hydrogen plays a crucial role in making industry more sustainable. However, as a recent article in Focus magazine shows, Germany has a "chicken and egg problem" when it comes to hydrogen. Planning security is needed to drive the necessary investment in hydrogen infrastructure. But industry is still hesitant, especially in uncertain times; no one wants to stick their neck out too far. This, in turn, does not provide an environment conducive to launching essential prerequisites, such as pipelines, storage facilities, or decentralized electrolysers. What does the future hold for Germany as a hydrogen location? Which stocks could benefit?
Read
Commented by André Will-Laudien on July 28th, 2025 | 07:15 CEST
Better than Nvidia and without AI – 185% with Veganz, Bayer, Novo Nordisk, and Nestlé in focus
It does not always have to be NVIDIA. German stocks are also performing well. Those who took advantage of Trump's tariff panic in April to buy in have since earned 75% with NVIDIA, but a whopping 185% with German plant-based nutrition expert, Veganz Group. Even the long-sidelined pharmaceutical giant Bayer has made an astonishing comeback with 50% growth, while Nestlé, supposedly an anchor in many portfolios, has lost 15%. Some call it selection luck, while others refer to it as sector rotation. It is currently apparent that the long, strong rally on international stock markets is benefiting only a few stocks. It remains fascinating that the stock market always celebrates when Donald Trump's tariff threats ultimately turn out to be less severe than initially expected. What remains for the economy, however, is less growth and high prices at the checkout. The new US policy stands for many things, but first and foremost, for less trade and economic downturn. How can investors still profit?
Read
Commented by Stefan Feulner on July 28th, 2025 | 07:10 CEST
Hensoldt, Almonty Industries, MTU Aero Engines – Profit-taking after milestone
The signs of a correction on global stock markets are growing. In addition to the historically high Shiller P/E ratio, call options reached their highest share since the meme stock euphoria of 2021 last week, accounting for almost 70% of total option volume. Market sentiment is extremely bullish, which could indicate an imminent consolidation. One of the most promising commodity companies of the future consolidated last week. Following outstanding news, investors cashed in, which could offer long-term entry opportunities.
Read
Commented by Fabian Lorenz on July 28th, 2025 | 07:05 CEST
Shares with up to 200% Upside! Barrick Mining, RENK, and Dryden Gold
RENK's share price has more than tripled in the current year, and analysts still see further upside. However, expectations for revenue growth and order intake are sky-high, so investors are advised to proceed with caution. According to analysts, Dryden Gold is set to triple in value. The Company is currently developing a high-grade deposit where visible gold can be seen on surface - a promising indicator of future resource potential. Analysts also see a bright future for Barrick Mining. With a gold price of USD 4,000, they estimate the stock could gain 50%—or potentially even more.
Read
Commented by Armin Schulz on July 28th, 2025 | 07:00 CEST
War, raw material shortages, cancer: Capitalize on megatrends with Rheinmetall, Antimony Resources, Merck KGaA
Three megatrends are expected to drive global markets in 2025. Revolutionary technologies, such as AI and cybersecurity, are fundamentally changing the defence sector. At the same time, demand for critical raw materials for defense, high-tech applications, and the energy transition is exploding, requiring new, sustainable supply chains. In parallel, the pharmaceutical industry is undergoing a dramatic shift due to advances in AI-driven research and intensified competition. These forces are shaping the future opportunities for companies. Those who are strategically positioned here will win, as key players Rheinmetall, Antimony Resources, and Merck KGaA demonstrate.
Read
Commented by André Will-Laudien on July 25th, 2025 | 07:05 CEST
Biotech turns to gold: Who is swallowing whom - or what? Evotec, BioNxt, Valneva, and Formycon are on the list!
The biotech sector is closely monitoring central bank interest rates. At present, however, inflation still seems a little too high to expect significant cuts. Accordingly, the European Central Bank left its key interest rates unchanged yesterday. Investors are now looking to Wall Street for signals on where rates might head in the second half of the year. However, due to the sharp price increases on the Nasdaq and existing undervaluations, takeover rumors are starting to circulate - and could materialize at any time. BioNxt, Evotec, and Valneva are on our watchlist. Where do the opportunities lie for investors?
Read
Commented by Nico Popp on July 25th, 2025 | 07:00 CEST
Key technology in the fight against cancer? Merck & Co., Vidac Pharma, AstraZeneca
Do you know what aerobic glycolysis is? No? Have you ever heard of the Warburg effect? Both terms describe the same phenomenon: cancer cells utilize glucose to produce lactate, even in the presence of oxygen and fully functional mitochondria. This is what distinguishes cancer cells from healthy cells. Current research suggests that targeted interventions in the Warburg effect could be suitable for killing cancer cells or making them more receptive to other therapies. Companies around the world are pushing forward research into this effect – the goal is nothing less than curing cancer. We present some of the companies and analyze whether their stocks could be good investments.
Read
Commented by Fabian Lorenz on July 24th, 2025 | 07:20 CEST
AI stocks: Buy SAP now? BioNTech surprises! NetraMark beats ChatGPT!
SAP shares performed poorly yesterday. However, the software company is running smoothly and making progress in expanding its AI and cloud business. Is now a good time to get in? Analysts see around 50% upside potential for NetraMark shares. The AI specialist supports Big Pharma in efficient drug development – a billion-dollar market. Now NetraAI has even beaten ChatGPT and DeepSeek! BioNTech is also betting on artificial intelligence. However, the Mainz-based company is currently only making headlines with a change in personnel, but this could change on August 4. Will there be new impetus soon?
Read